Press Releases

Compellis Pharmaceuticals Presents Results of Pilot Clinical Study at Obesity Society Annual Meeting

Novel patented weight loss approach was well tolerated by subjects

Boston, Mass., September 29, 2010 — Compellis Pharmaceuticals, Inc., an early-stage pharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, will present the results of its Phase I pilot clinical trial at the annual Obesity Society meeting. The meeting is being held from October 1-5, 2011 in Orlando Florida.

Pennington Biomedical Research Institute and Compellis Pharmaceuticals Complete Phase I Study of Novel and Patented Obesity Therapy

Novel weight loss approach was well tolerated by subjects

Boston, Mass., July 22, 2010 – Compellis Pharmaceuticals, Inc., an early-stage pharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today with its collaborator Pennington Biomedical Research Institute at Louisiana State University, that they have successfully completed a human Phase I pilot clinical trial. Study subjects were given one of three doses of the drug (CP404) to test safety, tolerability and impact on smell perception. CP404 is a calcium channel blocker and has been used in oral dosage form to treat high blood pressure. The novel mechanism for the drug therapy is based on the inhibition of calcium channel activity in the olfactory pathways Local blockade of the sense of smell is predicted to reduce individuals' interest in food intake and lead to therapeutic weight reduction.

Compellis Pharmaceuticals, Inc. Awarded Second Broad Patent from the U.S. Patent Office for Novel Obesity Therapy

Drug blocks olfactory sensory perception and may lead to weight loss

Boston, Mass., October 27, 2008 – Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that they have been issued a second broad patent (7,435,407) by the U.S. Patent and Trademark Office (USPTO) for its invention entitled "Inhibition of olfactory neurosensory function to treat obesity and related disorders."

Pennington Biomedical Research Institute Receives FDA Approval to Begin Phase I Studies of Compellis Pharmaceuticals’ Novel and Patented Obesity Therapy

Therapy blocks olfactory sensory perception that may lead to a reduction in appetite and cause weight loss

Boston, Mass., January 7, 2008 – Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that its collaborator Pennington Biomedical Research Institute at Louisiana State University, with Principal Investigator Dr. Frank Greenway, MD, has received FDA approval to begin human clinical Phase I studies.

Compellis Pharmaceuticals Awarded Patent for its Therapeutic Platform for Treating Obesity

Patent covers therapy that blocks olfactory sensory perception which may lead to reduction in appetite and weight loss.

Boston, Mass., December 5, 2006 — Compellis Pharmaceuticals, a biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that it has been issued a patent (7,138,107) by the U.S. Patent and Trademark Office (USPTO) for its invention entitled "Inhibition of olfactory neurosensory function to treat obesity and related disorders."

Compellis Pharmaceuticals, Inc.

Main Menu